[6-(1,2,3,4-四氢萘基)]乙腈 | 3160-18-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: [6-(1,2,3,4-四氢萘基)]乙腈
• 英文名称: <6-(1,2,3,4-tetrahydronaphthalenyl)>acetonitrile
• 英文别名: 5,6,7,8-tetrahydronaphthalene-2-acetonitrile；(5,6,7,8-tetrahydro-[2]naphthyl)-acetonitrile；(5,6,7,8-Tetrahydro-[2]naphthyl)-acetonitril；2-Cyanmethyl-5,6,7,8-tetrahydro-naphthalin；1.2.3.4-Tetrahydronaphthyl-7-acetonitril；2-Cyanmethyl-5,6,7,8-tetrahydro-naphthaline；2-(5,6,7,8-tetrahydronaphthalen-2-yl)acetonitrile
• CAS: 3160-18-7
• 化学式: C₁₂H₁₃N
• 分子量: 171.242
• InChiKey: AXGFMKFEMOBRMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  [6-(1,2,3,4-四氢萘基)]乙腈 在 sodium hydroxide 、 氯化亚砜 作用下， 生成 (5,6,7,8-tetrahydronaphthalen-2-yl)acetyl chloride
  参考文献：
  名称：

  Kiprianow; Uschenko, Zhurnal Obshchei Khimii, 1950, vol. 20, p. 134,141; engl. Ausg. S. 139, 144

  摘要：

  DOI：
• 作为产物：
  描述：

  6-羟甲基-1,2,3,4-四氢萘 在 氯化亚砜 、 苯 作用下， 生成 [6-(1,2,3,4-四氢萘基)]乙腈
  参考文献：
  名称：

  The Catalytic Dehydrogenation of 2-Substituted-5,6,7,8-tetrahydronaphthalene Derivatives¹

  摘要：

  DOI：

  10.1021/ja01246a027

文献信息

• Piperazine derivatives and methods of use
  申请人：Chen J. Jian

  公开号：US20050014749A1

  公开（公告）日：2005-01-20

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于治疗疼痛和炎症介导的疾病等方面有效。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物，以及用于预防和治疗涉及疼痛、炎症等疾病或其他疾病或病况的药物组合物和方法。该发明还涉及制备这类化合物的方法，以及在这类方法中有用的中间体。
• [EN] ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'INTÉGRINE ALPHA V BÊTA 6 ET ALPHA V BÊTA 1 ET LEURS UTILISATIONS
  申请人：DICE MOLECULES SV INC

  公开号：WO2022192545A1

  公开（公告）日：2022-09-15

  Provided herein are alpha V beta 6 and alpha V beta 1 integrin inhibitors, methods of making such alpha V beta 6 and alpha V beta 1 integrin inhibitors, pharmaceutical compositions of alpha V beta 6 and alpha V beta 1 integrin inhibitors, and methods of treating and/or preventing various medical disorders in a subject by administering to the subject in need thereof alpha V beta 6 and alpha V beta 1 integrin inhibitors.

  本文提供了αVβ6和αVβ1整合素抑制剂，制备这种αVβ6和αVβ1整合素抑制剂的方法，αVβ6和αVβ1整合素抑制剂的药物组合物，以及通过向需要此类抑制剂的受试者投与αVβ6和αVβ1整合素抑制剂来治疗和/或预防各种医学疾病的方法。
• Derivatives of piperazine and higher homologues thereof for the treatment of inflammation-related disorders
  申请人：Amgen Inc.

  公开号：EP1878728A2

  公开（公告）日：2008-01-16

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions thereof. The compounds claimed can be used in methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like.

  所选化合物可有效治疗疼痛和疾病，如炎症介导的疾病。本发明包括新型化合物及其药学上可接受的衍生物、药物组合物。所要求的化合物可用于预防和治疗涉及疼痛、炎症等疾病和其他弊病或病症的方法。
• Antihyperglycemic activity of novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides
  作者：John W. Ellingboe、Thomas R. Alessi、Terence M. Dolak、Thomas T. Nguyen、John D. Tomer、Frieda Guzzo、Jehan F. Bagli、Michael L. McCaleb

  DOI：10.1021/jm00085a002

  日期：1992.4

  A series of substituted 3H-1,2,3,5-oxathiadiazole-2-oxides (6) was prepared and tested for antihyperglycemic activity in the db/db mouse, a model for type 2 (non-insulin dependent) diabetes mellitus. The oxathiadiazoles 6 were synthesized by a two-step sequence: treatment of a substituted acetonitrile (4) with hydroxylamine to give the corresponding amidoxime (5) and cyclization with thionyl chloride to yield 6. In terms of potency, the 2-naphthalenylmethyl group (as in compound 3) was found to be the optimal substituent in this series. Compound 3 was approximately 5 times more potent than ciglitazone (1).
• Synthetic Studies in the Isoquinoline Series
  作者：Everett M. Schultz、R. T. Arnold

  DOI：10.1021/ja01174a003

  日期：1949.6